Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 25 of 90 for:    hidradenitis suppurativa

Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository (HS PROGRESS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04115566
Recruitment Status : Not yet recruiting
First Posted : October 4, 2019
Last Update Posted : October 4, 2019
Sponsor:
Information provided by (Responsible Party):
Haley Naik, University of California, San Francisco

Brief Summary:
Hidradenitis suppurativa (HS) is a common and debilitating skin disease that is poorly understood and understudied. As a result, little is known about disease prognosis and few effective treatments exist for this condition. This prospective observational cohort study aims to comprehensively characterize the clinical and biological features of HS. The results of this research will provide a basis for the development of an HS clinical classification system and identification of potential treatments for HS.

Condition or disease
Hidradenitis Suppurativa

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 3000 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 10 Years
Official Title: Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository
Estimated Study Start Date : October 1, 2019
Estimated Primary Completion Date : September 1, 2029
Estimated Study Completion Date : September 1, 2029

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Primary Objective [ Time Frame: 2019-2029 ]
    The primary aim of this study is to identify clinical and biologic characteristics of hidradenitis suppurativa.


Secondary Outcome Measures :
  1. Secondary Objective [ Time Frame: 2019-2029 ]
    Secondary aims include correlating alterations in clinical and biological characteristics with disease status, and identifying genetic variants that predict disease progression or response to therapy.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   10 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
HS Patients
Criteria

Inclusion Criteria:

  1. Male or female ≥ 10 years of age
  2. Diagnosis of HS by a dermatologist or practitioner experienced in making a diagnosis of HS
  3. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.

Exclusion Criteria:

1. Inability to give informed consent or unavailability of a parent/guardian who is able and willing to give informed consent.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04115566


Contacts
Layout table for location contacts
Contact: Maia Paul, MPH 415-502-4741 Maia.Paul@ucsf.edu

Locations
Layout table for location information
United States, California
University of California San Francisco Not yet recruiting
San Francisco, California, United States, 94115
Principal Investigator: Haley B Naik, MD, MHSc, FAAD         
Sponsors and Collaborators
University of California, San Francisco
Investigators
Layout table for investigator information
Principal Investigator: Haley B Naik, MD, MHSc, FAAD University of California, San Francisco

Layout table for additonal information
Responsible Party: Haley Naik, Assistant Professor of Dermatology, University of California, San Francisco
ClinicalTrials.gov Identifier: NCT04115566     History of Changes
Other Study ID Numbers: 18-27002
First Posted: October 4, 2019    Key Record Dates
Last Update Posted: October 4, 2019
Last Verified: October 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hidradenitis Suppurativa
Hidradenitis
Sweat Gland Diseases
Skin Diseases
Skin Diseases, Bacterial
Bacterial Infections
Skin Diseases, Infectious
Infection
Suppuration